Methods and compositions for the prevention and treatment of disease
The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
1. A method for treating a disease or condition characterized by a reduction of function, decreased expression levels of, or a deficiency in the COL4A3 gene in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the aromatic-cationic peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the pharmaceutically acceptable salt comprises acetate, tartrate, or trifluoroacetate salt.
3. The method of claim 1 , wherein the disease or condition is characterized by a reduction of function in COL4A3 compared to a normal control subject.
4. The method of claim 1 , wherein the disease or condition is characterized by a deficiency in COL4A3 compared to a normal control subject.
5. The method of claim 1 , wherein the disease or condition is characterized by decreased expression levels of COL4A3 compared to a normal control subject.
6. The method of claim 1 , wherein the subject is human.
7. The method of claim 1 , wherein peptide treatment results in elevated Mfn1 expression and/or function compared to an untreated subject having said disease or condition.
8. The method of claim 1 , wherein the aromatic-cationic peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intraperitoneally, intradermally, intraocularly, iontophoretically, transmucosally, or intramuscularly.
9. The method of claim 1 , wherein the peptide is administered daily for 6 weeks or more.
10. The method of claim 1 , wherein the peptide is administered daily for 12 weeks or more.
11. The method of claim 1 , further comprising separately, sequentially or simultaneously administering one or more additional therapeutic agents to the subject.
12. The method of claim 11 , wherein the additional therapeutic agents are selected from the group consisting of: angiotensin II converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor blockers (ARBs), HMG-CoA reductase inhibitors, aldosterone inhibitors, aliskiren, calcineurin inhibitors, endothelin receptor antagonists sulodexide, vasopeptidase inhibitors, anti-transforming growth factor-β1 antibody, chemokine receptor 1 blockers, bone morphogenetic protein-7, PPARγ agonists, and BAY-12-9566.